Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

3rd Affiliated Hospital of ZhengZhou University

1 abstract

Abstract
Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial.
Org: 3rd Affiliated Hospital of ZhengZhou University,